Q-omics provides the consensus-scored MIR3613 profile across patient tissues and cancer cell-line models. MIR3613 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR3613 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, MIR3613 RNA expression shows 9,455 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight UCEC, COAD, and DLBC as cancer lineages where MIR3613 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3613 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3613 survival associations across molecular data types. MIR3613 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3613 RNA expression–survival associations across cancer types. High MIR3613 expression shows unfavorable associations in UCEC, CESC, READ, ACC, MESO and OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR3613 RNA expression.
This table summarizes MIR3613 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3613. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3613 shows higher tumor expression in COAD, LIHC, ESCA, KIRP, BRCA and STAD. The COAD box plot shows higher MIR3613 RNA expression in tumor versus normal tissue (log2 FC = +0.411, t-test p = .008).
This table shows molecular features associated with MIR3613 in patient tissues and cancer cell lines. In patient samples, MIR3613 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
